Navigation Links
ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program

BARCELONA, July 17, 2012 /PRNewswire/ --

  • The sigma-1 receptor (S1R) is an important development target for innovative medications to treat neuropathic pain, for which new medications are much needed.
  • Developed by ESTEVE, E-52862 is a potent, highly selective NCE with a novel mechanism of action (S1R antagonism) currently being evaluated for the treatment of pain.
  • In studies conducted to date in preclinical models, a direct relationship between dose of E-52862, levels of E-52862 interacting with the S1R in the brain, and analgesic activity (pain-relieving effect) was demonstrated.
  • Importantly, in these models, the pain-relieving effect of E-52862 is maintained with repeated treatment.
  • E-52862 has completed a rigorous Phase I programme that included more than 300 subjects.  Results show good safety, tolerability, pharmacodynamic and pharmacokinetic profiles.
  • Phase II clinical trials evaluating E-52862 are ongoing.

ESTEVE announces the recent publication in the British Journal of Pharmacology[1] of important preclinical data that furthers understanding of its highly potent and selective, once-daily, S1R antagonist E-52862, developed by the ESTEVE Research and Development (R&D) team.

José Miguel Vela, PhD, responsible for ESTEVE Drug Discovery and Preclinical Development, stated, "These data demonstrate the role of ESTEVE's E-52862, a NCE from our programme of sigma-1 receptor antagonists, as a novel modulator of pain sensitisation and relief.  It also highlights that the target of this new compound, the sigma-1 receptor, is correlated mechanistically with the compound's ability to relieve pain."

Key data reported in the publication highlight the pharmacological activity of the selective S1R antagonist E-52862, which acts on the central nervous system (CNS) in various preclinical models of pain.  Importantly, the data show E-52862's highly targeted mode of action (MOA) acts specifically on the S1R in relation to pain models evaluated, meaning normal perception and sensations remain unaffected.  In addition, not only was pain relief sustained with repeated administration of E-52862, but in specific models, some improvement was observed over time; likely due to the MOA of E-52862 and not to changes in concentrations of E-52862 in plasma and brain, which were similar after single and repeated E-52862 administration.

A close correlation was observed between the extent that E-52862 was able to enter the brain and bind with the S1R in the CNS and the level of pain relief exerted by E-52862.  In studies of CNS excitability, E-52862 significantly reduced the amplification of the message (hyperexcitability) coming from pain sensors, without affecting non-pain fibers that transmit other types of sensory stimuli.

The S1R also modulates another receptor - mu-opioid - and affects its activity.  As a result, E-52862 may enhance the pain relief effects of opioids (potentiation of opioid analgesia) without increasing opioid-related side effects.

The Phase I programme with E-52862 is complete and included more than 300 subjects (more than 250 received E-52862).  Results from the programme show good safety, tolerability, pharmacodynamic and pharmacokinetic profiles at all doses of E-52862 tested.

Today, ESTEVE's E-52862 clinical programme focuses on pain management - highlighting both neuropathic pain and the potentiation of opioid analgesia.  The Phase II clinical trial programme for E-52862 started in early 2012.

E-52862, whose MOA is both novel and complementary to that of other pain medications, could provide a much-needed addition to future pain management choices with, perhaps, the option to be used as monotherapy, as well as in combination with other pain relief compounds, depending on the type of patient and clinical indication.


ESTEVE is a leading pharmaceutical chemical group based on Barcelona (Spain) with significant international presence.  Since it was founded in 1929, ESTEVE has been firmly committed to excellence in healthcare, dedicating its efforts to innovative R&D of new medicines for unmet medical needs and focusing on high science and credible, evidence-based research.  ESTEVE has a strong partnership approach to drug discovery, development and commercialisation.  The company works both independently and in collaboration to bring new, differentiated best-in-class treatments to patients who need them. ESTEVE currently has a team of about 2800 professionals, and has subsidiaries and production facilities in several European countries, USA, China and Mexico.

About E-52862 and Pain R&D at ESTEVE

ESTEVE's dedicated in-house R&D team is focused on the development of novel pain medications, an area of high unmet medical need.  Considerable progress in the knowledge of the biology and pharmacology of the S1R (a unique protein) during the last few years has re-energised research into the potential benefits of S1R ligands in a range of neurological and psychiatric conditions.

New data has addressed key questions on modulation, MOA and pathophysiology of the S1R.  The proprietary ESTEVE S1R knockout mouse demonstrated a direct role of the S1R in sensitisation phenomena associated with neuropathic pain mechanisms and behaviours.  E-52862 induces robust, dose-dependent analgesic activity in multiple preclinical neuropathic pain models.  E-52862 could have potential applications for other neurological and psychiatric indications.  Besides information reported here, an extensive preclinical regulatory safety package is available for E-52862 (including 13-week repeat dose toxicity studies in rats, dogs and monkeys).  E-52862 also has robust intellectual property protection.

ESTEVE's portfolio in pain also includes a technology platform-derived new co-crystal entity (E-58425) developed by the in-house R&D team at ESTEVE.  E-58425 has completed Phase I, with Phase II currently ongoing.  E-58425 is being developed for moderate to severe acute and chronic pain.


[1] Romero L et al.  Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitisation.  Br J Pharmacol 2012 Mar 9 [Epub ahead of print]. doi: 10.1111/j.1476-5381.2012.01942.x.

For more information and enquiries into partnership opportunities, please contact:

Mark Mayhew, PhD, Head of ESTEVE R&D Strategic Partnering, Tel. +34-93-446-6000,

For corporate communications/media enquiries, please contact:

Ma. Ángels Valls, Head of ESTEVE Corporate Communications, Tel. +34-93-446-6000,

Visit our new R&D website:

Follow us on Twitter: @ESTEVE_news

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Integrity Life Sciences Announces Two US Patents
2. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
3. RxAlly Announces Addition Of Experienced Corporate Counsel Tom OGrady To The Companys Leadership Team
4. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
5. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
6. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
7. FDAnews announces Fourth Annual Supplier Quality Congress
8. Ampio Pharmaceuticals Announces Proposed Public Offering
9. Sono-Tek Announces First Quarter Results
10. iMedX Announces Acquisition of Electronic Medical Transcription Services, Inc.
11. MDHI Enhances Service Offerings with New Options for Customers of Americas Largest Warehouse Club Chain - Announces New Extended Concierge Services
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):